Theresa L. Werner, M.D.

Locations

Schedule An Appointment	Clinical Office Address
(801) 585-0250	Huntsman Cancer Hospital Clinic 2B, GYN 1950 Circle of Hope Salt Lake City, UT 84112 Map

Bio

Theresa L. Werner, M.D.

Assistant Professor, Division of Oncology, Department of Medicine

Theresa L. Werner, M.D., is an assistant professor in the Division of Oncology, Department of Medicine, at the University Of Utah School Of Medicine, an Investigator at the Huntsman Cancer Institute, and a member of the Experimental Therapeutics Program. Dr. Werner is a specialist in adult hematology and medical oncology, and her main areas of interest include breast cancer and gynecologic malignancies (cancers of the ovary, uterus, cervix, and vagina).

Dr. Werner earned her bachelor’s degree from Indiana University in Bloomington, Indiana, and her medical degree from Indiana University School of Medicine, in Indianapolis, Indiana. She then completed a residency in internal medicine and a chief medical residency at the University Of Utah School Of Medicine, where she received awards for excellence in teaching and the clinical care of patients. Dr. Werner then completed a fellowship in hematology and medical oncology at the University of Utah and the Huntsman Cancer Institute. She is board certified in internal medicine, hematology, and oncology.

Dr. Werner is a member of the gynecologic and breast cancer programs at the Huntsman Cancer Institute. She sees patients with these types of cancers in her clinic as well as those patients at high risk for breast and ovarian cancer in the Family Cancer Assessment Clinic. Dr. Werner is a member of several professional societies including the American Society of Clinical Oncology, the Southwest Oncology Group, and the Gynecology Oncology Group, where she serves as a member of the Medical Oncology Committee. She also serves on the National Cancer Institute’s Cervical Cancer Task Force and the National Cancer Comprehensive Network (NCCN) Panel for Ovarian Cancer which defines national standards for the oncologic care of ovarian cancer. Dr. Werner is heavily involved in clinical and translational research and is active in the experimental therapeutics and phase one clinical trial program. Dr. Werner serves as the principal investigator for numerous clinical trials in breast and gynecologic cancers.

Board Certification and Academic Information

Academic Departments	Internal Medicine - Assistant Professor
Academic Divisions	Oncology
Board Certification	American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology)

Board Certification and Academic Information

Academic Departments	Internal Medicine - Assistant Professor
Academic Divisions	Oncology
Board Certification	American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology)

Academic Office Locations

Academic Office Phone Number	Academic Office Address
(801) 585-0255	Huntsman Cancer Institute Oncology 2000 Circle of Hope Salt Lake City, UT 84112

Academic Bio

Theresa L. Werner, M.D.

Assistant Professor, Division of Oncology, Department of Medicine

Dr. Werner earned her bachelor’s degree from Indiana University in Bloomington, Indiana, and her medical doctorate from Indiana University School of Medicine, in Indianapolis, Indiana. She completed her residency in internal medicine and a chief medical residency at the University Of Utah School Of Medicine, where she received awards for excellence in teaching and the clinical care of patients. Dr. Werner then completed a fellowship in hematology and medical oncology at the University of Utah and the Huntsman Cancer Institute. She is board certified in internal medicine, hematology, and oncology.

Dr. Werner is an Assistant Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine, an Investigator at the Huntsman Cancer Institute, and a member of the Experimental Therapeutics Program. Dr. Werner is a specialist in adult hematology and medical oncology, with a focus on breast cancer and gynecologic malignancies (cancers of the ovary, uterus, cervix, and vagina). She also sees patients and families at high risk for breast and ovarian cancer in the Family Cancer Assessment Clinic.

Dr. Werner is a member of several professional societies including the American Society of Clinical Oncology, the Southwest Oncology Group, and the Gynecology Oncology Group, where she serves as a member of the Medical Oncology Committee. She also serves on the National Cancer Institute’s Cervical Cancer Task Force and the National Cancer Comprehensive Network (NCCN) Panel for Ovarian Cancer, which defines national standards for the oncologic care of ovarian cancer. Dr. Werner is heavily involved in clinical and translational research, with an emphasis on breast and gynecologic malignancies, and is active in the experimental therapeutics and phase one clinical trial programs. She currently serves as the principal investigator for numerous clinical trials, including cooperative group, industry sponsored, and investigator-initiated trials at HCI, with an emphasis on utilizing tumor profiling to better define patients that will best respond to targeted therapy.

Education History

Type	School	Degree
Fellowship	University of Utah School of Medicine Hematology/Oncology	Chief Fellow
Other Training	University of Utah, Clinical Investigation Training Program
Fellowship	University of Utah School of Medicine Hematology/Oncology	Fellow
Chief Resident	University of Utah School of Medicine Internal Medicine	Chief Resident
Residency	University of Utah School of Medicine Internal Medicine	Resident
Internship	University of Utah School of Medicine Internal Medicine	Intern
Professional Medical	Indiana University Medicine	M.D.
Undergraduate	Indiana University Biology	B.S.

Selected Provider Publications

Journal Article

1. Horvath LE, Werner T, Boucher K, Jones (2013)The relationship between tumor size and stage in early versus advanced ovarian cancer.  Medical Hypotheses, 80(5),684-7
2. Lum MM, Belnap TW, Frandsen J, Brown AP, Sause WT, Soisson AP, Dodson MK, Werner T, Gaffney D(2013)Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer.  American Journal of Clinical Oncology: cancer clinical trials,
3. Albright F, Teerlink C, Werner TL, Cannon-Albright L(2012)Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site.  BMC Cancer, 12138
4. Tantravahi SK, Werner T(2012)Locally recurrent endometrial cancer: a case report.  Journal of the National Comprehensive Cancer Network, 10(4),442-5
5. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer M(2012)Ovarian Cancer, Version 3.2012.  Journal of the National Comprehensive Cancer Network, 10(11),1339-1349
6. Smit WS, Sufliarsky J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Spirtos N, Oza A, Dirix L, El-Hashimy M, Acharyya S, Tan EY, Weber D, Schellens J(2012)A phase II study of Patupilone (EPO906) in patients with platinum- resistant or -refractory ovarian cancer. January 2012.  Clinical Ovarian Cancer and Other Gynecologic Malignancies,
7. Gaffney DK, Werner T(2012)Curative Treatment for Recurrent and Metastatic Cervical Cancer  Expert Review of Obstetrics & Gynecology, 7(6),521-523
8. Yadav BS, George P, Sharma SC, McClennan E, Martino mA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh, Sokol L, Morris G(2012)Primary Non Hodgkin’s Lymphoma of the Ovary: Current Clinical Practice  Seminars in Oncology,
9. Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner T(2011)Epithelial ovarian cancer.  Journal of the National Comprehensive Cancer Network, 9(1),82-113
10. Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney D(2010)A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.  International Journal of Radiation Oncology, Biology, Physics, 78(1),127-35
11. Montejo M, Werner TL, Gaffney (2009)Current challenges in clinical management of endometrial cancer.  Advanced Drug Delivery Reviews, 61(10),883-9
12. Werner TL, Agarwal N, Carney HM, Rodgers G(2007)Management of cancer-associated thrombotic microangiopathy: what is the right approach?  American Journal of Hematology, 82(4),295-8
13. Lo T, van Der Schalie E, Werner T, Brun YV, Din (2004)A temperature-sensitive mutation in the dnaE gene of Caulobacter crescentus that prevents initiation of DNA replication but not ongoing elongation of DNA.  Journal of Bacteriology, 186(4),1205-12

Review

1. Lim HY, Werner T, Agarwal N, Rodgers GM(2008)Management of thrombotic microangiopathy with underlying malignancy. Helix Review Series: Oncology. 2008; 13(2):18-21  Helix Review Series, 13(2),18-21

Case Report

1. Wong, J and Werner T(2011)Kikuchi-Fujimoto Lymphadenitis: A Case of Misdiagnosed Breast Cancer.  The American Journal of Case Reports, 1280-82
2. Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers G(2006)Acquired amegakaryocytic thrombocytopenic purpura.  American Journal of Hematology, 81(2),132-5

Letter

1. Camp NJ, Werner TL, Cannon-Albright L(2008)Familial myeloma.  New England Journal of Medicine, 359(16),1734-5; author reply 1735

Abstract

1. Munster P, VanDer Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock (2012)PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). Oral Presentation European Society of Medical Oncology, September 2012, Vienna, Austria. [Abstract]. European Society of Medical Oncology.  ,
2. Agarwal, N, Sahu M, Abhyankar J, Werner TL, Benjamin B, Srinivas NR, Sharma (2011)A drug-drug interaction study of Everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF2, PDGF, and EphB4 receptros, in patients with advanced urologic tumors. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2011. Published in J Clin Oncol 29:15s, 2011 (suppl; abstr e15077).  , 29(15s),
3. Cohen, AL, Schabel M, Bild AH, Werner T(2011)VAST (Valproic Acid Signature Trial): A proof-of-principle study correlating pharmacology, pathology, and advanced imaging with genomic prediction of drug sensitivity in breast cancer. Poster Presentation Oncology Annual Meeting, Chicago, Illinois, June 2011. (suppl; abstr TPS148)  , 29(15s),
4. Bild AH, Sun Y, Soldi R, Conner T, Walker D, Werner T, Spira A, Andrulis I, Buys SS, Johnson (2009)A Genomic Biomarker for Breast Cancer Development in High-Risk Women. Poster Presentation. CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2009. Published in Cancer Res 2009; 69(Suppl.): (24). Dec 15, 2009.  , 69(24),
5. Smit WM, Sufliarksy J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Delaney R, Li J, Weber D, Schellens JH(2009)A phase II study evaluating the safety and efficacy of Patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 2009. Published in J Clin Oncol 27:15s, 2009 (suppl; abstr 5563).  , 27(15s),5563
6. Horvath LE, Werner T, Jones K(2007)The Relationship between Tumor Size and Stage in Early versus Advanced Ovarian Cancer: A Retrospective Chart Review. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2007. Published in J Clin Oncol, 25:18s, 2007 (suppl; abstr 5580).  , 25(18s),5580

Poster

1. Raaum S, Tantravahi S, Werner T(2012)Neurocysticercosis or Neuro-metastatic Merkel Cell Carcinoma? Poster Presentation (Clinical Vignette), April 2012.  ,
2. Raaum S, Tantravahi S, Werner T(2011)Neurocysticercosis or Neuro-metastatic Merkel Cell Carcinoma? Poster Presentation, Winner  ,
3. Camp NJ, Werner TL, Cannon-Albright L(2007)Hematologic Malignancies in the Utah Population Database. Oral Presentation.  ,
4. Camp NJ, Werner TL, Cannon-Albright L(2007)Multiple Myeloma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma: Evidence for Overlapping Genetic Etiologies. Platform Presentation.  ,
5. Camp NJ, Werner TL, Cannon-Albright L(2007)Pleiotropic Genetic Etiologies in Hematological Malignancies: Evidence from the Utah Population Database. Oral Presentation., ,  ,
6. Camp NJ, Werner TL, Cannon-Albright L(2007)Strong Evidence for a Genetic Component to Multiple Myeloma and Pleiotrophy with Other Hematologic Malignancies.  ,
7. Camp NJ, Werner TL, Cannon-Albright L(2007)The Familiality of Multiple Myeloma in the Utah Population Database.  ,

News

• University of Utah's Role in Angelina Jolie's Decision for Mastectomy

Video